Literature DB >> 8254057

Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a).

M F Linton1, R V Farese, G Chiesa, D S Grass, P Chin, R E Hammer, H H Hobbs, S G Young.   

Abstract

The B apolipoproteins, apo-B48 and apo-B100, are key structural proteins in those classes of lipoproteins considered to be atherogenic [e.g., chylomicron remnants, beta-VLDL, LDL, oxidized LDL, and Lp(a)]. Here we describe the development of transgenic mice expressing high levels of human apo-B48 and apo-B100. A 79.5-kb human genomic DNA fragment containing the entire human apo-B gene was isolated from a P1 bacteriophage library and microinjected into fertilized mouse eggs. 16 transgenic founders expressing human apo-B were generated, and the animals with the highest expression had plasma apo-B100 levels nearly as high as those of normolipidemic humans (approximately 50 mg/dl). The human apo-B100 in transgenic mouse plasma was present largely in lipoproteins of the LDL class as shown by agarose gel electrophoresis, chromatography on a Superose 6 column, and density gradient ultracentrifugation. When the human apo-B transgenic founders were crossed with transgenic mice expressing human apo(a), the offspring that expressed both transgenes had high plasma levels of human Lp(a). Both the human apo-B and Lp(a) transgenic mice will be valuable resources for studying apo-B metabolism and the role of apo-B and Lp(a) in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254057      PMCID: PMC288508          DOI: 10.1172/JCI116927

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Isolation of RNA using guanidinium salts.

Authors:  R J MacDonald; G H Swift; A E Przybyla; J M Chirgwin
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

2.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 3.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

Review 4.  Review of lipid-lowering clinical trials in relation to observational epidemiologic studies.

Authors:  H A Tyroler
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

5.  Genetic factors controlling structure and expression of apolipoproteins B and E in mice.

Authors:  A J Lusis; B A Taylor; D Quon; S Zollman; R C LeBoeuf
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

6.  A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.

Authors:  L M Powell; S C Wallis; R J Pease; Y H Edwards; T J Knott; J Scott
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

7.  Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice.

Authors:  B Paigen; D Mitchell; K Reue; A Morrow; A J Lusis; R C LeBoeuf
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia.

Authors:  S G Young; S J Bertics; L K Curtiss; J L Witztum
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

9.  Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47.

Authors:  S G Young; J L Witztum; D C Casal; L K Curtiss; S Bernstein
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

10.  Structure of the human apolipoprotein B gene.

Authors:  B D Blackhart; E M Ludwig; V R Pierotti; L Caiati; M A Onasch; S C Wallis; L Powell; R Pease; T J Knott; M L Chu
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

View more
  50 in total

1.  Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.

Authors:  M Raabe; M M Véniant; M A Sullivan; C H Zlot; J Björkegren; L B Nielsen; J S Wong; R L Hamilton; S G Young
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.

Authors:  R V Farese; M M Véniant; C M Cham; L M Flynn; V Pierotti; J F Loring; M Traber; S Ruland; R S Stokowski; D Huszar; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  SR-BI (Scavenger Receptor BI), Not LDL (Low-Density Lipoprotein) Receptor, Mediates Adrenal Stress Response-Brief Report.

Authors:  Misa Ito; Xiang Ye; Qian Wang; Ling Guo; Dan Hao; Deborah Howatt; Alan Daugherty; Lei Cai; Ryan Temel; Xiang-An Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-06-11       Impact factor: 8.311

5.  Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J Mice.

Authors:  Lakshmi Narasimha Rao; Thiruvelselvan Ponnusamy; Sheena Philip; Rupak Mukhopadhyay; Vijay V Kakkar; Lakshmi Mundkur
Journal:  Lipids       Date:  2015-07-16       Impact factor: 1.880

6.  Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.

Authors:  J Borén; K Olin; I Lee; A Chait; T N Wight; T L Innerarity
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

7.  A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine.

Authors:  S G Young; C M Cham; R E Pitas; B J Burri; A Connolly; L Flynn; A S Pappu; J S Wong; R L Hamilton; R V Farese
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 8.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

9.  Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a).

Authors:  S P McCormick; J K Ng; S Taylor; L M Flynn; R E Hammer; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis.

Authors:  Andreas Hermansson; Daniel F J Ketelhuth; Daniela Strodthoff; Marion Wurm; Emil M Hansson; Antonino Nicoletti; Gabrielle Paulsson-Berne; Göran K Hansson
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.